Compositions comprising salbutamol sulphate

Patent metadata

Field	Value
Publication number	US-10039828-B2
Application number	US-201615357279-A
Country	US
Kind code	B2
Filing date	Nov 21, 2016
Priority date	Oct 12, 2011
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

First claim

The invention claimed is:

1. A pharmaceutical composition that is free of polar excipients and 1,1,1,2-tetrafluoroethane (R-134a), said composition comprising:
(a) a propellant component comprising 1,1-difluoroethane (R-152a),
(b) a surfactant component comprising oleic acid; and
(c) a drug component consisting of salbutamol sulphate.

2. The pharmaceutical composition of claim 1 which consists essentially of components (a), (b) and (c).

3. A pharmaceutical composition that is free of 1,1,1,2-tetrafluoroethane (R-134a) for delivery from a pressurised container, said composition consisting essentially of:
(a) a propellant component consisting essentially of 1,1-difluoroethane (R-152a),
(b) a surfactant component comprising oleic acid; and
(c) a drug component consisting of salbutamol sulphate.

4. The pharmaceutical composition of claim 1 or claim 3 which consists entirely of components (a), (b) and (c).

5. The pharmaceutical composition of claim 1 , wherein the propellant component consists entirely of 1,1-difluoroethane (R-152a).

6. The pharmaceutical composition of claim 1 , wherein the surfactant component consists entirely of oleic acid.

7. The pharmaceutical composition of claim 1 , wherein the surfactant component consists of oleic acid and at least one additional surfactant compound selected from polyethylene glycols, polyvinylpyrrolidone, and lecithin.

8. The pharmaceutical composition of claim 1 , wherein the surfactant component consists of oleic acid and at least one additional surfactant compound selected from ethyl oleate, sorbitan trioleate, isopropyl myristate, polyethylene glycol 300, polyoxyethylene 20 sorbitan monooleate and monolaurate, propoxylated polyethyleneglycol, polyvinylpyrrolidone, and lecithin.

9. A sealed container that contains the pharmaceutical composition as claimed in claim 1 .

10. The sealed container of claim 9 which is a pressurized container for use with a metered dose inhaler (MDI).

11. A metered dose inhaler (MDI) fitted with a pressurized container as claimed in claim 10 .

12. A method for treating a patient suffering or likely to suffer from a respiratory disorder which comprises administering to the patient a therapeutically or prophylactically effective amount of the pharmaceutical composition as claimed in claim 1 .

13. The method of claim 12 , wherein the respiratory disorder is asthma.

14. The method of claim 12 , wherein the pharmaceutical composition is delivered to the patient using a metered dose inhaler (MDI).

15. A method for manufacturing the pharmaceutical composition as claimed in claim 1 , said method comprising the steps of:
introducing a weighed amount of the drug component into an open container from which the drug component will ultimately be released as an aerosol spray using a medication delivery device;
fitting a valve device onto the container;
introducing the propellant component, in liquid form, through the valve into the container under pressure; and
introducing the surfactant component through the valve into the container under pressure.

16. The method of claim 15 , wherein the propellant component is mixed together with the surfactant component and the resulting liquid mixture introduced into the container under pressure via the valve.

Assignees

• Mexichem Amanco Holding Sa

Inventors

• Corr Stuart
• Noakes Timothy James

Classifications

• A61P11/06

  Antiasthmatics · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K47/06 Primary

  Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite · CPC title

• A61K31/137

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K9/008 Primary

  comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI] · CPC title